Noven Pharma files low-dose mesylate salt of paroxetine for Menopause - 01-Sep-2012

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., has submitted to the FDA a New Drug Application (NDA) seeking approval to market low-dose mesylate salt of paroxetine (LDMP) for the treatment of vasomotor symptoms associated with menopause. In March 2012, Noven announced completion of the LDMP clinical development program, which included two Phase III studies involving an aggregate of 1,180 subjects from more than 130 centers across the U.S. Phase III study results for LDMP are scheduled to be presented at the North American Menopause Society Annual Meeting in October 2012

Related News

Related Women's Health and Obs/Gyn Information

Women's Health and Obs/Gyn Clinical Guidelines

Antenatal and postnatal mental health

NICE

Antenatal care: Routine care for the healthy pregnant woman

NICE

Women's Health and Obs/Gyn Clinical Trials

Bone Healing in Healthy and Post-menopausal Osteoporotic Women

Clinicaltrials.gov 26 March 2013

TMMR Register Study (TMMR-RS)

Clinicaltrials.gov 19 March 2013

Women's Health and Obs/Gyn Medical Journal Abstracts

Efficacy and safety of intraoperative intravenous methadone during general anaesthesia for caesarean delivery: a retrospective case-control study

International Journal of Obstetric Anesthesia 10 December 2012

Insertion of an intrathecal catheter following accidental dural puncture: a meta-analysis

International Journal of Obstetric Anesthesia 06 December 2012

Women's Health and Obs/Gyn Medical Apps

Obstetics and Gynecology On Call

£0.69

Women's Health

Free

Related Women's Health and Obs/Gyn Drugs

Back to top

Latest News

10 May 2015
23 May 2013
22 May 2013